

Amendments to the Claims:

1. (Currently amended) A method of generating an HIV-specific cytotoxic T-cell (CTL) response in a host possessing MHC class I HLA A2 molecules, which comprises:

administering to the host a T-helper molecule to prime T-helper cells of the immune system of the host, and

subsequently administering to the host a mixture of said T-helper molecule and a T-cell inducing HIV molecule which bind capable of binding to MHC class I HLA A2 molecules to generate an HIV-specific cytotoxic T-cell (CTL) response in the host.

2. and 3. (Cancelled)

4. (Previously amended) The method of claim 1 wherein said T-helper molecule is CLP-243 (SEQ ID NO:10).

5. (Original) The method of claim 1 wherein said T-helper molecule is administered with an adjuvant.

6. (Previously amended) The method of claim 1 wherein said T-cell inducing HIV molecule includes a peptide having an amino acid sequence which is that of a portion of an HIV-1 antigen, said peptide containing at least one T-cell epitope.

7. (Previously amended) The method of claim 6 wherein said peptide having an amino acid sequence which is that of a portion of the Rev protein of HIV-1.

8. (Original) The method of claim 6 wherein said peptide is a lipopeptide.

9. (Original) The method of claim 8 wherein the lipid is palmitoyl or cholesterol.

10. (Currently amended) A method of generating an HIV-specific cytotoxic T-cell (CTL) response in a host possessing MHC class I HLA A2 molecules, which comprises:

administering to the host a T-helper molecule which is CLP-243 (SEQ ID No: 10) to prime T-helper cells of the immune system of the host, and subsequently administering to the host a mixture of said T-helper molecule and a T-cell inducing HIV molecule capable of binding to MHC class I HLA A2 molecule, said T-cell inducing HIV molecule being and which is a lipopeptide which is CLP-175 or CLP-176, CLP-176 to generate an HIV-specific cytotoxic T-cell (CTL) response in the host.

11. (Original) The method of claim 6 wherein said mixture is administered with an adjuvant.

12. (Currently amended) An isolated peptide consisting of amino acids 52 to 116 (SEQ ID No:9) of the sequence of the Rev protein of HIV-1 LAI isolate and containing T-cell epitopes within amino acids 63 to 73 (SEQ ID NO:3), 74 to 83 (SEQ ID NO:5) and 102 to 110 (SEQ ID NO:8).

13. (Currently amended) A peptide consisting of an amino acid sequence which is amino acids 52 to 116 (SEQ ID No: 9) of the sequence of the Rev protein of HIV-1 LAI isolate and containing T-cell epitopes within amino acids 63 to 73 (SEQ ID No: 3), 74 to 83 (SEQ ID No: 5) and 102 to 110 (SEQ ID No: 8), said peptide being in the form of a lipopeptide.

14. (Original) The method of claim 13 wherein the lipid is palmitoyl or cholesterol.

15. (Original) The method of claim 13 wherein the lipopeptide is CLP-175 or CLP-176